Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.
CHDI Foundation, Inc. is a unique drug discovery organization focused exclusively on rapidly developing therapies that slow the progression of HD. It is the biggest funder and organizer of HD research worldwide, but many people affected by HD have never heard of it. During CHDI’s Annual Therapeutics Conference in Palm Springs, HDBuzz spoke exclusively to three of its scientific leaders.
Our third and final daily report from CHDI’s annual HD therapies meeting in Palm Springs, covering chemicals that can help neurons to survive, and insights into CHDI’s most advanced experimental drug programs.
Our second daily report from CHDI’s annual HD therapies meeting in Palm Springs, devoted to problems with energy generation and chemical pathways … and ways we might be able to fix them
In the first of our daily reports from CHDI’s annual HD therapies meeting in Palm Springs, we report on strategies to turn off the harmful gene and get brain cells communicating more effectively.
The connection between cellular energy levels and HD is more complicated than we previously thought, but in a way that opens a door to more possible treatments. It seems drugs that actually slow down the production of energy can rescue cells with the HD mutation from dysfunction and death.
Over the last few years, CHDI Inc. has become the largest single driving force behind the development HD treatments. CHDI’s annual therapeutics conference in Palm Springs, California, brings together pharmaceutical companies, biotechnology companies and researchers to share their latest, hottest findings and talk about the path to a cure. HDBuzz will be reporting from the conference – and we want your questions!
HDBuzz is now live! Your source for Huntington’s disease research news, in plain language, written by scientists, for the global HD community. Reliable, impartial and free to share, HDBuzz will bring you solid reasons to have hope, by explaining latest news from the worldwide effort to find effective treatments for HD.
A drug used to treat the symptoms of Alzheimer’s disease might be beneficial in HD through altering the balance of good and bad messages coming into neurons. New research in HD mice suggests that low doses of memantine might be best, and hopefully a planned trial of low-dose memantine in HD patients will give us the answer.
We all know that exercise and staying active are good for everyone, whether or not they are at risk of developing HD. A new study of lifestyle activities in people with the HD mutation suggests that staying active is even more important in HD, and that passive habits – especially during the teenage years – might be one factor that can cause earlier onset of HD symptoms.